

# Samuel Deshayes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1862602/publications.pdf>

Version: 2024-02-01

54  
papers

690  
citations

687363

13  
h-index

610901

24  
g-index

76  
all docs

76  
docs citations

76  
times ranked

964  
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-O1, non-O139 <i>Vibrio cholerae</i> bacteraemia: case report and literature review. <i>SpringerPlus</i> , 2015, 4, 575.	1.2	99
2	Neurological Adverse Effects Attributable to $\beta$ -Lactam Antibiotics: A Literature Review. <i>Drug Safety</i> , 2017, 40, 1171-1198.	3.2	72
3	Neurotoxocarisis: a systematic literature review. <i>Infection</i> , 2016, 44, 565-574.	4.7	71
4	Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux. <i>American Journal of Hematology</i> , 2019, 94, 1314-1324.	4.1	55
5	Efficacy of Anakinra for Various Types of Crystal-Induced Arthritis in Complex Hospitalized Patients: A Case Series and Review of the Literature. <i>Mediators of Inflammation</i> , 2015, 2015, 1-7.	3.0	37
6	Hypocomplementemia is associated with worse renal survival in ANCA-positive granulomatosis with polyangiitis and microscopic polyangiitis. <i>PLoS ONE</i> , 2018, 13, e0195680.	2.5	30
7	Characteristics and outcomes of patients with ophthalmologic involvement in giant-cell arteritis: A case-control study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 335-341.	3.4	27
8	Observational Study of a French and Belgian Multicenter Cohort of 23 Patients Diagnosed in Adulthood With Mevalonate Kinase Deficiency. <i>Medicine (United States)</i> , 2016, 95, e3027.	1.0	24
9	Efficacy of Continuous Interleukin 1 Blockade in Mevalonate Kinase Deficiency: A Multicenter Retrospective Study in 13 Adult Patients and Literature Review. <i>Journal of Rheumatology</i> , 2018, 45, 425-429.	2.0	23
10	Steroid-sparing effect of anakinra in giant-cell arteritis: a case series with clinical, biological and iconographic long-term assessments. <i>Rheumatology</i> , 2021, 61, 400-406.	1.9	20
11	Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification. <i>Rheumatology</i> , 2019, 58, 1731-1739.	1.9	19
12	Specific changes in faecal microbiota are associated with familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1398-1404.	0.9	18
13	Positive predictive value of hospital discharge diagnosis code to identify immunoglobulin A vasculitis in France: A validation study. <i>European Journal of Internal Medicine</i> , 2017, 43, e18-e19.	2.2	15
14	Infections and AA amyloidosis: An overview. <i>International Journal of Clinical Practice</i> , 2021, 75, e13966.	1.7	12
15	ANCA and anti-glomerular basement membrane double-positive patients: A systematic review of the literature. <i>Autoimmunity Reviews</i> , 2021, 20, 102885.	5.8	12
16	Concomitant association of giant cell arteritis and malignancy: a multicenter retrospective case-control study. <i>Clinical Rheumatology</i> , 2019, 38, 1243-1249.	2.2	11
17	Tumour necrosis factor receptor-1 associated periodic syndrome (TRAPS)-related AA amyloidosis: a national case series and systematic review. <i>Rheumatology</i> , 2021, 60, 5775-5784.	1.9	11
18	Giant cell arteritis-related aortic dissection: A multicenter retrospective study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 430-435.	3.4	11

#	ARTICLE	IF	CITATIONS
19	A Worldwide Pharmacoepidemiologic Update on Drug-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the Era of Targeted Therapies. <i>Arthritis and Rheumatology</i> , 2022, 74, 134-139.	5.6	10
20	Real-life analysis of the causes of death in patients consecutively followed for giant cell arteritis in a French centre of expertise. <i>Rheumatology</i> , 2021, 60, 5080-5088.	1.9	9
21	Chronic hepatic involvement in the clinical spectrum of A20 haploinsufficiency. <i>Liver International</i> , 2021, 41, 1894-1900.	3.9	9
22	Tolerance of glucocorticoids in giant cell arteritis: a study of patient-reported adverse events. <i>Rheumatology</i> , 2022, 61, 3567-3575.	1.9	9
23	Clinical Effect of Alpha-1 Antitrypsin Deficiency in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Results from a French Retrospective Monocentric Cohort. <i>Journal of Rheumatology</i> , 2019, 46, 1502-1508.	2.0	8
24	Impact of Glucocorticoid Cumulative Doses in a Real-Life Cohort of Patients Affected by Giant Cell Arteritis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1034.	2.4	8
25	In familial Mediterranean fever, soluble TREM-1 plasma level is higher in case of amyloidosis. <i>Innate Immunity</i> , 2019, 25, 487-490.	2.4	7
26	Prevalence of Anti-Neutrophil Cytoplasmic Antibodies and Associated Vasculitis in COPD Associated With Alpha-1 Antitrypsin Deficiency. <i>Chest</i> , 2020, 158, 1919-1922.	0.8	6
27	Prevalence of Raynaud Phenomenon and Nailfold Capillaroscopic Abnormalities in Fabry Disease. <i>Medicine (United States)</i> , 2015, 94, e780.	1.0	5
28	Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment. <i>Oncolmmunology</i> , 2018, 7, e1450712.	4.6	4
29	Second-line and beyond: treatment options for primary persistent and chronic immune thrombocytopenia. <i>Platelets</i> , 2020, 31, 291-299.	2.3	4
30	An overview of the perspectives on experimental models and new therapeutic targets in giant cell arteritis. <i>Autoimmunity Reviews</i> , 2020, 19, 102636.	5.8	4
31	IVIg increases interleukin-11 levels, which in turn contribute to increased platelets, VWF and FVIII in mice and humans. <i>Clinical and Experimental Immunology</i> , 2021, 204, 258-266.	2.6	4
32	Cause of death and risk factors for mortality in AA amyloidosis: A French retrospective study. <i>European Journal of Internal Medicine</i> , 2020, 82, 130-132.	2.2	4
33	Severe cryptococcal-associated neurological immune reconstitution inflammatory syndrome in a renal transplant recipient treated with adalimumab. <i>Transplant Infectious Disease</i> , 2016, 18, 461-465.	1.7	3
34	Interest of immunodeficiency screening in adult after admission in medical intensive care unit for severe infection, a retrospective and a prospective study: the Intensive Care Unit and Primary and Secondary Immunodeficiency (ICUSPID) study. <i>Infection</i> , 2019, 47, 87-93.	4.7	3
35	Impact of Giant Cell Arteritis and Its Treatment on the Patient's Quality of Life: A Single-Center Self-Assessment Study. <i>Frontiers in Medicine</i> , 2021, 8, 777310.	2.6	3
36	Early infectious risk in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis according to remission-induction therapy. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 161-173.	1.1	3

#	ARTICLE	IF	CITATIONS
37	Pneumococcal Meningitis and Endocarditis: A Case Report. American Journal of Medicine, 2016, 129, e19-e20.	1.5	2
38	An updated list of drugs suspected to be associated with immune thrombocytopenia based on the WHO pharmacovigilance database. Blood, 2022, 140, 922-927.	1.4	2
39	Multiple cranial neuropathies following zoledronic acid infusion: a relationship? Clinical features and pathogenic discussion concerning a case. Osteoporosis International, 2016, 27, 2627-2629.	3.1	1
40	AA amyloidosis associated with Fabry disease. International Journal of Clinical Practice, 2020, 74, e13577.	1.7	1
41	Typical Familial Mediterranean Fever associated with the heterozygous missense sequence p.T577N variant of the MEFV gene: Report on two Northern European Caucasians relatives in France. Joint Bone Spine, 2020, 87, 251-255.	1.6	1
42	POS0118â€¦A WORLDWIDE PHARMACOEPIDEMOLOGICAL UPDATE OF DRUG-ASSOCIATED ANCA-ASSOCIATED VASCULITIS AT THE TIME OF TARGETED THERAPIES. Annals of the Rheumatic Diseases, 2021, 80, 270.1-270.	0.9	1
43	POS0338â€¦STEROID-SPARING EFFECT OF ANAKINRA IN GIANT-CELL ARTERITIS: A CASE SERIES WITH CLINICAL, BIOLOGICAL AND ICONOGRAPHIC LONG-TERM ASSESSMENTS. Annals of the Rheumatic Diseases, 2021, 80, 397.1-397.	0.9	1
44	AA Amyloidosis in the Course of HIV Infection: A Report of 19 Cases Including 4 New French Cases and a Comprehensive Review of Literature. Nephron, 2021, 145, 675-683.	1.8	1
45	AB0587â€¦Antineutrophilic cytoplasmic antibody-associated vasculitis and hypocomplementemia: clinical impact and outcome. , 2017, , .		0
46	FRI0345â€¦Clinical impact of ALPHA-1-ANTITRYPSIN deficiency in granulomatosis with polyangiitis. , 2017, , .		0
47	THU0337â€¦Classification of antineutrophilic cytoplasmic antibody-associated vasculitis and clinical impact and outcome. , 2017, , .		0
48	AB0588â€¦Concomitant association of giant cell arteritis and malignancy: a multicenter retrospective case-control study. , 2017, , .		0
49	Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report. Clinical Rheumatology, 2018, 37, 1119-1122.	2.2	0
50	Response to Letter to the Editor. Innate Immunity, 2020, 26, 232-233.	2.4	0
51	POS1343â€¦ABNORMAL ELECTROCHEMICAL SKIN CONDUCTANCE VALUES IN PATIENTS WITH AA AMYLOIDOSIS. Annals of the Rheumatic Diseases, 2021, 80, 954.1-954.	0.9	0
52	POS0831â€¦EARLY INFECTIOUS RISK IN PATIENTS WITH NEWLY-DIAGNOSED ANTI-NEUTROPHILCYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS ACCORDING TO THE REMISSION-INDUCTION THERAPY: A FRENCH MONOCENTRIC RETROSPECTIVE STUDY INCLUDING 145 PATIENTS. Annals of the Rheumatic Diseases, 2021, 80, 669.2-669.	0.9	0
53	Abnormal electrochemical skin conductance values in patients with AA amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, , 1-2.	3.0	0
54	On the Determinants ofIDO Activity in Patients With Familial Mediterranean Fever. Modern Rheumatology, 2022, , .	1.8	0